In today’s session DexCom, Inc. (DXCM) registered an unusually high (185) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious DXCM increase. With 185 contracts traded and 6094 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: DXCM161021C00095000 closed last at: $0.45 or 50% up. About 267,964 shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has risen 25.56% since March 3, 2016 and is uptrending. It has outperformed by 17.21% the S&P500.
Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on November, 2. They expect $-0.13 EPS, down 85.71% or $0.06 from last year’s $-0.07 per share. After $-0.24 actual EPS reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -45.83% EPS growth.
DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage
Out of 12 analysts covering Dexcom (NASDAQ:DXCM), 10 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 83% are positive. Dexcom has been the topic of 16 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, February 24 by Benchmark. On Friday, August 7 the stock rating was maintained by Piper Jaffray with “Buy”. As per Monday, November 2, the company rating was initiated by Morgan Stanley. The company was downgraded on Wednesday, September 14 by BTIG Research. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Overweight” rating given on Thursday, September 17 by JP Morgan. Leerink Swann upgraded DexCom, Inc. (NASDAQ:DXCM) on Thursday, October 15 to “Outperform” rating. The rating was maintained by Jefferies with “Buy” on Wednesday, February 24. As per Thursday, October 15, the company rating was upgraded by Sterne Agee CRT. JP Morgan maintained the stock with “Overweight” rating in Wednesday, February 24 report. Desjardins Securities upgraded the stock to “Buy” rating in Friday, September 16 report.
According to Zacks Investment Research, “Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.”
Insitutional Activity: The institutional sentiment increased to 1.35 in 2016 Q2. Its up 0.40, from 0.95 in 2016Q1. The ratio improved, as 30 funds sold all DexCom, Inc. shares owned while 77 reduced positions. 46 funds bought stakes while 98 increased positions. They now own 82.43 million shares or 5.55% more from 78.09 million shares in 2016Q1.
Amalgamated National Bank holds 13,126 shares or 0.07% of its portfolio. Janus Mgmt Ltd Liability last reported 0.12% of its portfolio in the stock. California Pub Employees Retirement Sys holds 0.01% or 111,300 shares in its portfolio. Wells Fargo And Mn has 2.23M shares for 0.07% of their US portfolio. Pacad Invest has 1,600 shares for 0.02% of their US portfolio. Blackrock Group Limited last reported 0% of its portfolio in the stock. American Century, a Missouri-based fund reported 806,639 shares. American Intl Gp Inc last reported 0% of its portfolio in the stock. Nationwide Fund Advsrs last reported 0.06% of its portfolio in the stock. Westfield Management Co L P has 710,001 shares for 0.46% of their US portfolio. American Research & Mngmt Co has 200 shares for 0.01% of their US portfolio. Granahan Inv Inc Ma holds 209,600 shares or 0.61% of its portfolio. Weiss Multi reported 36,450 shares or 0.22% of all its holdings. Qs Limited Liability Corp reported 36,358 shares or 0.02% of all its holdings. Paradigm Asset Limited Liability reported 9,200 shares or 0% of all its holdings.
Insider Transactions: Since April 11, 2016, the stock had 0 buys, and 65 sales for $59.10 million net activity. SAYER KEVIN R sold 7,000 shares worth $559,457. GREGG TERRANCE H had sold 2,169 shares worth $147,492 on Monday, April 11. On Friday, September 9 the insider SKYLER JAY S sold $2.35 million. MOY JEFFREY sold $884,800 worth of stock or 10,000 shares. $906,399 worth of DexCom, Inc. (NASDAQ:DXCM) was sold by LORD JONATHAN T MD. Shares for $934,588 were sold by Pacelli Steven Robert on Tuesday, August 23. DOUBLEDAY RICHARD also sold $289,224 worth of DexCom, Inc. (NASDAQ:DXCM) shares.
Dexcom, Inc. is a medical device company. The company has a market cap of $7.04 billion. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. It currently has negative earnings. The Company’s products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
DXCM Company Profile
Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.
Another recent and important DexCom, Inc. (NASDAQ:DXCM) news was published by Prnewswire.com which published an article titled: “Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 …” on September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.